Oncology Centers
Explainable multimodal Risk Stratification and tumor board preparation embedded in your existing clinical pathway.
S-02-02
Five common bottlenecks Oncology Centers face under fragmented information and high-volume clinical assessment.
High-risk cohorts have long follow-up intervals, and suspicious signals rarely enter a unified priority queue.
Imaging, pathology, and omics conclusions sit in separate systems, making tumor board preparation time-consuming.
Post-treatment recurrence and progression signals lack an auditable dynamic stratification mechanism.
Black-box scores cannot support departmental QC, teaching, or external audit.
Existing EHR / PACS environments are stable and cannot absorb a rip-and-replace integration risk.
S-02-03
Pain points, Neurovia capabilities, and customer outcomes aligned one to one.
| Pain point | Solution | Customer outcome |
|---|---|---|
| Early screening misses | Screening and follow-up Risk Stratification with automatic tumor board preparation queueing | Highly suspicious cases surfaced sooner |
| Fragmented information | Multimodal Fusion engine consolidates imaging / pathology / omics evidence | Tumor board preparation time significantly reduced |
| Follow-up hard to track | Follow-up window risk re-assessment and structured summaries | Recurrence monitoring more continuous and auditable |
| Conclusions hard to explain | Feature contribution, confidence intervals, and QC audit trails | Supports teaching, QC, and compliance review |
| High replacement cost | Standard DICOM / HL7 / FHIR integration with on-premises deployment | Pilot embedding achievable in 4–8 weeks |
S-02-04
From daily screening to tumor board preparation—covering high-frequency Oncology Center workflows.
Scenario 01
Same-day screening and follow-up cases are automatically stratified by risk. Highly suspicious cases are prioritized to oncology specialists and the tumor board preparation list, reducing manual case identification.
Scenario 02
Before consultation, key imaging slices, pathology conclusions, and omics signals are consolidated into an auditable structured summary for multidisciplinary discussion.
Scenario 03
Post-treatment follow-up milestones trigger dynamic re-stratification. Abnormal changes enter the review queue with a complete decision trail for QC spot checks.
S-02-05
Typical results from pilot institutions (varies by data quality and workflow maturity).
Reductions come mainly from data gathering and summary preparation; consultation coordination changes less.
Share of screening / follow-up cases entering the standard clinical workflow rises as calibration progresses.
S-02-06
Published cases in this industry and upcoming content.
Receive an industry whitepaper outline, data checklist, and 30-day pilot path.